Literature DB >> 8794008

Neutralization of HIV-1 by antibody.

Q J Sattentau1.   

Abstract

The humoral immune response to HIV-1 has been extensively studied over the past few years and considerable advances have been made in understanding the dynamics and specificity of the neutralizing antibody component during and after seroconversion. Despite this, there is still no clear understanding of the role of neutralizing antibodies in controlling or preventing HIV-1 infection. Candidate vaccines have been based on immunogens designed to elicit a neutralizing response, but the recent vaccine trial failures force us to reconsider the role of neutralizing antibodies in HIV-1 infection and the type of vaccine preparation used.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794008     DOI: 10.1016/s0952-7915(96)80044-6

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  13 in total

1.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.

Authors:  A Valenzuela; J Blanco; B Krust; R Franco; A G Hovanessian
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41.

Authors:  B Labrosse; O Pleskoff; N Sol; C Jones; Y Hénin; M Alizon
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.

Authors:  H Ruppach; P Nara; I Raudonat; Z Elanjikal; H Rübsamen-Waigmann; U Dietrich
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

5.  Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.

Authors:  P W Parren; I Mondor; D Naniche; H J Ditzel; P J Klasse; D R Burton; Q J Sattentau
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

6.  Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity.

Authors:  A Brelot; N Heveker; O Pleskoff; N Sol; M Alizon
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

7.  Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.

Authors:  Ramu A Subbramanian; Jingwu Xu; Emil Toma; Richard Morisset; Eric A Cohen; José Menezes; Ali Ahmad
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

8.  Plasma and salivary IgA subclasses and IgM in HIV-1-infected individuals.

Authors:  Xueling Wu; Susan Jackson
Journal:  J Clin Immunol       Date:  2002-03       Impact factor: 8.317

9.  Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Harold Legg; Elaine Kan; Anne Fong; Stephen R Coates; Louisa Leung; Mark Wininger; John J Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

10.  Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.

Authors:  Saurabh Mehandru; Terri Wrin; Justin Galovich; Gabriela Stiegler; Brigitta Vcelar; Arlene Hurley; Christine Hogan; Sandhya Vasan; Hermann Katinger; Christos J Petropoulos; Martin Markowitz
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.